<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03478267</url>
  </required_header>
  <id_info>
    <org_study_id>0584-16-RMB</org_study_id>
    <nct_id>NCT03478267</nct_id>
  </id_info>
  <brief_title>The Relationship Between Fetal Baseline Heart-rate and the Level of Acetyl-choline Esterase in Fetal Blood</brief_title>
  <official_title>The Relationship Between Fetal Baseline Heart-rate and the Level of Acetyl-choline Esterase in Fetal Blood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pregnant women between 32-41 weeks' gestation designated for either vaginal birth or cesarean&#xD;
      section will be recruited for the study. Data regarding maternal resting heart rate and fetal&#xD;
      baseline heart rate as depicted on the monitor will be collected. A blood sample will be&#xD;
      acquired from the parturient and the umbilical cord as well as a sample from the placenta&#xD;
      will be obtained. Levels of Acetyl Choline Esterase (AChE) will be determined from all&#xD;
      aforementioned samples. Statistical correlation between fetal baseline heart rate and fetal&#xD;
      and maternal AChE levels will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pregnant women between 32-41 weeks' gestation designated for either vaginal birth or cesarean&#xD;
      section will be recruited for the study. After signing an informed consent, data regarding&#xD;
      maternal resting heart rate and fetal baseline heart rate as depicted on the monitor will be&#xD;
      collected.&#xD;
&#xD;
      Patients will be divided into 2 equal groups according to fetal baseline heart rate:&#xD;
&#xD;
        1. st group-fetal heart rate between 110-130 beats per minute (bpm).&#xD;
&#xD;
        2. nd group-fetal heart rate between 140-160 bpm. A blood sample will be acquired from the&#xD;
           parturient and the umbilical cord as well as a sample from the placenta will be&#xD;
           obtained. Levels of Acetyl Choline Esterase (AChE) will be determined from all&#xD;
           aforementioned samples. Statistical correlation between fetal baseline heart rate and&#xD;
           fetal and maternal AChE levels will be assessed.&#xD;
&#xD;
      Data regarding demographic, medical and obstetric information of the participants will be&#xD;
      obtained from the hospital's electronic records.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Days</target_duration>
  <primary_outcome>
    <measure>AChE levels in fetal blood</measure>
    <time_frame>Up to 5 minutes post delivery (either vaginal or cesarean)</time_frame>
    <description>AChE levels obtained from the fetal umbilical cord after birth</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AChE levels in maternal blood</measure>
    <time_frame>Up to 5 minutes post delivery (either vaginal or cesarean)</time_frame>
    <description>AChE levels obtained from maternal peripheral blood after birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AChE levels in the placenta</measure>
    <time_frame>Up to 30 minutes post delivery (either vaginal or cesarean)</time_frame>
    <description>AChE levels obtained from the placenta after birth</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Fetal Heart Failure (Disorder)</condition>
  <arm_group>
    <arm_group_label>Fetal heart rate 110-130 bpm</arm_group_label>
    <description>Pregnancies in which the fetal baseline heart rate is between 110 beats per minute and 130 beats per minute.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fetal heart rate 140-160 bpm</arm_group_label>
    <description>Pregnancies in which the fetal baseline heart rate is between 140 beats per minute and 160 beats per minute.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>AChE levels</intervention_name>
    <description>AChE levels in peripheral blood tests from maternal blood, fetal umbilical cord and placenta.</description>
    <arm_group_label>Fetal heart rate 110-130 bpm</arm_group_label>
    <arm_group_label>Fetal heart rate 140-160 bpm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women between 32 and 41 weeks' gestation undergoing either vaginal or cesarean&#xD;
        delivery with a fetal baseline heart rate of 110-130 beats per minute and 140-160 beats per&#xD;
        minute.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women between 32 and 41 weeks' gestation undergoing either vaginal or&#xD;
             cesarean delivery with a fetal baseline heart rate of 110-130 beats per minute and&#xD;
             140-160 beats per minute.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Delivery before 32 weeks of gestation&#xD;
&#xD;
          2. Maternal bradycardic (&lt;60) or tachycardic (&gt;100) resting heart rate.&#xD;
&#xD;
          3. Fetal bradycardia (&lt;110) or tachycardia (&gt;160).&#xD;
&#xD;
          4. Suspected chorioamnionitis&#xD;
&#xD;
          5. Maternal diseases which can affect her heart rate such as:&#xD;
&#xD;
               1. Cardiac disease (including arrhythmias)&#xD;
&#xD;
               2. Diseases of the thyroid gland&#xD;
&#xD;
               3. Rheumatic diseases&#xD;
&#xD;
          6. Use of medication which alters heart rate such as:&#xD;
&#xD;
               1. Beta blockers&#xD;
&#xD;
               2. Beta agonists&#xD;
&#xD;
               3. Cocaine, amphetamines&#xD;
&#xD;
          7. Use of Pethidine and Phenergan during delivery&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female pregnant patients and their fetuses</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vered Lamhot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vered Lamhot, MD</last_name>
    <phone>0547720990</phone>
    <email>veryshick@hotmal.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rambam hospital</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vered Lamhot, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 20, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>Vered Lamhot MD</investigator_full_name>
    <investigator_title>Primary investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

